Sublingual Administration of Amfexa (Immediate-Release Dextroamphetamine) Tablets
Amfexa tablets (dexamfetamine sulfate) are intended for oral use, not sublingual administration. Amfexa 5 mg patient leaflet (PIL)
Sublingual use represents off-label administration with a higher risk of unpredictable exposure compared with the labeled route, which can increase the likelihood of stimulant-related adverse effects and toxicity. Amfexa 5 mg patient leaflet (PIL)
Medication Route and Label-Intended Clinical Use
Amfexa tablets are described as a medicine intended for oral use. Amfexa 5 mg patient leaflet (PIL)
Amfexa is positioned as a specialist-initiated ADHD treatment and is used within a broader treatment program (psychological, educational, and social measures). Amfexa 5 mg patient leaflet (PIL)
Toxicity and Adverse Effects Likely to Be Exacerbated by Unpredictable Exposure
Central nervous system stimulant toxicity can occur with excess amphetamine exposure. [1]
Major labeled adverse-effect domains relevant to potential increased systemic exposure include:
- Cardiovascular events and physiologic stimulation, including sudden death in vulnerable patients, stroke and myocardial infarction in adults, and increases in blood pressure and heart rate. [1]
- Psychiatric adverse effects, including new or worse behavior and thought problems, bipolar illness, and aggression or hostility. [1]
- Gastrointestinal adverse effects, including dry mouth, unpleasant taste, diarrhea, constipation, and anorexia/weight loss. [1]
- High abuse and dependence potential, with the label emphasizing avoidance of prolonged administration. [1]
Sublingual Administration-Specific Safety Considerations
Sublingual administration is not supported by the Amfexa tablet leaflet, which specifies oral administration with a drink of water and guidance relative to meals. Amfexa 5 mg patient leaflet (PIL)
Because sublingual administration changes the delivery pathway from the labeled GI/oral route to the mucosal route, absorption timing and peak exposure can become less predictable compared with labeled oral dosing. Amfexa 5 mg patient leaflet (PIL)
That unpredictability increases the practical risk that a dose intended to produce a specific clinical effect may instead produce higher peak stimulant effects, with greater probability of the cardiovascular, psychiatric, and GI adverse effects described above. [1]
Appropriate Clinical Use of Amphetamine-Type IR Products
Stimulant treatment with amphetamine-class agents should be used according to labeled dosing, including patient selection and monitoring for adverse cardiovascular and psychiatric effects. [1]
Patients should not receive dosing changes or non-labeled routes aimed at increasing speed of onset without clinical supervision, due to the label’s emphasis on serious cardiovascular risk, monitoring needs, and abuse potential. [1]
Common Pitfalls to Avoid
- Using Amfexa tablets via a non-labeled route such as sublingual administration despite the leaflet specifying oral use. Amfexa 5 mg patient leaflet (PIL)
- Increasing risk for adverse events in patients with predisposing conditions by introducing exposure patterns that could raise peak effects. [1]
- Extending or misusing stimulant dosing patterns, given the labeled high abuse and dependence potential. [1]